Rheumnow Podcast
Sleep Apnea Smart Watches (10.13.2023)
Oct 13, 2023
Dr. Jack Cush, a rheumatology expert, dives into the latest in medical news, including the recent approval of the Samsung Galaxy Watch for sleep apnea monitoring. He discusses polymyalgia rheumatica and innovative treatment approaches in rheumatology. Cush highlights new findings on inflammatory myopathies and the FDA’s approval of cecukinumab for arthritis. He also connects ACL injuries to accelerated osteoarthritis risks and reveals reproductive health concerns within scleroderma patients, showcasing significant health disparities.
19:51
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Effective management of Polymyalgia Rheumatica often begins with a prednisone dose of 12.5 to 25 mg, impacting remission rates significantly.
- Delays in diagnosing psoriatic arthritis highlight the necessity for improved patient education and proactive referrals to enhance early treatment.
Deep dives
Overview of Polymyalgia Rheumatica Management
Polymyalgia Rheumatica (PMR) is commonly treated with prednisone, with an initial dose typically ranging from 12.5 to 25 mg per day. Achieving remission is possible during the tapering process, though 40 to 60% of patients may relapse. Experts suggest that many practitioners prefer a starting dose of 15 mg, rarely exceeding 30 mg to manage symptoms effectively. Additionally, it has been noted that bilateral shoulder pain is more prevalent in PMR cases compared to isolated hip complaints, emphasizing the need for careful diagnosis.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
